Cullinan Therapeutics

start line beginning road path starting point journey
Biotech

Cullinan CEO sets tone for bispecific's upcoming lupus readout

While CAR-T's 100% remission rate has set the benchmark in lupus, Cullinan's CEO argues the bar is “very different” for an off-the-shelf regimen.
Angus Liu Feb 7, 2025 5:00am
On target clinical trial success bullseye score

Cullinan plans approval push for NSCLC drug after ph. 2 win

Jan 29, 2025 6:15am
Deal terminate tear up end deal scrap

Cullinan, after $25M deal, hands back bispecific to Harbour

Aug 8, 2024 10:10am
Graphic image of a compass above an unfolded map Orange background color

Cullinan rebrands, halts lymphoma trial in autoimmune refocus

Apr 16, 2024 10:05am
Photo of five sailboats setting out in the same direction over dark blue water

Cullinan plucks US rights to Harbour BioMed's novel bispecific

Feb 13, 2023 7:00pm